Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients

Date

21 Oct 2023

Session

Poster session 18

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Kin Nam Kwok

Citation

Annals of Oncology (2023) 34 (suppl_2): S594-S618. 10.1016/S0923-7534(23)01939-7

Authors

K.N. Kwok1, K.M. Cheung2, S.J.L. Lam3, H.S. Lam4, S.M. Yip5, S. Lam6, O.P. Chiu4, P.Y.M. Woo7, W. Sung2, J.C. Chow2, K. Bao2, G.T.C. Cheung2, A.K.Y. Chan8, E.Y.H. Fong8, S.K.K. Ng9, K.C.M. Cheung2, H.L. Leung10, D.M.Y. Kan5, H.H.Y. Yiu2, D.C.C. Lam11

Author affiliations

  • 1 Department Of Mechanical And Aerospace Engineering, HKUST - The Hong Kong University of Science and Technology, na - Kowloon/HK
  • 2 Department Of Clinical Oncology, Queen Elizabeth Hospital, Kowloon/HK
  • 3 Faculty Of Medicine, The Chinese University of Hong Kong, Sha Tin/HK
  • 4 Department Of Medicine, Kwong Wah Hospital, Kowloon/HK
  • 5 Department Of Surgery, Kwong Wah Hospital, Kowloon/HK
  • 6 Department Of Surgery, Addenbrooke's Hospital, CB2 0QQ - Cambridge/GB
  • 7 Department Of Neurosurgery, The Chinese University of Hong Kong - Prince of Wales Hospital, 0000 - Sha Tin/HK
  • 8 Department Of Medicine, Queen Elizabeth Hospital, Kowloon/HK
  • 9 Department Of Surgery, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin/HK
  • 10 Department Of Oncology, United Christian Hospital, Kowloon/HK
  • 11 Department Of Mechanical And Aerospace Engineering, HKUST - The Hong Kong University of Science and Technology, Kowloon/HK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 968P

Background

Current guidelines for hepatocellular carcinoma (HCC) screening in patients with chronic liver disease (CLD) recommend ultrasound with or without alpha-fetoprotein (AFP) every 6 months. The sensitivity of AFP and USG are low for early stage HCC. Following our previous study which identified a novel routine blood test signature for HCC, this study aims to develop a high-dimensional data classifier which accounts for the intricate interactions between these blood parameters for the detection of HCC. Its performance is then compared with AFP.

Methods

Records from 2000 to 2018 were retrieved from a population-based clinical database of >200k patients, the Hong Kong Hospital Authority Data Collaboration Laboratory. CLD (hepatitis/ cirrhosis) patients with and without HCC were identified with ICD codes, antiviral drug history, virology test and radiology reports. Decompensated cases were excluded. Blood records within one month before the diagnosis of HCC and CLD patients were retrieved. The records retrieved included all components of CBC, LFT, RFT and clotting profile. Data from 2000-2015 were split into training and testing cohorts in an 8:2 ratio while data from 2016-2018 were used as the validation set. Machine learning models were applied and their performances were compared with AFP.

Results

The cohort yielded 223,862 patients including 31,149 with HCC (45.9% hepatitis-associated) and 192,713 without. Results from the test set (n = 12528; 3279 HCC) showed promise in safely excluding non-HCC patients with a sensitivity of 90% and negative predictive value of 97%. The model’s high sensitivity maintained steady from late to early stage HCC while that of AFP halved. Our model increases HCC detection rate via USG from 19% to 50% compared to current protocol, indicating potential use in imaging prioritization and cost-saving in HCC surveillance.

Conclusions

An AI classifier for HCC detection is developed from routine blood test patient data. Its performance tested using an ultra-large cohort is consistently high without degradation across all stages with marked superiority to AFP for early stage HCC detection. Currently, multicenter prospective validation is being performed in Hong Kong.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The Hong Kong University of Science and Technology.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.